$GCTK
GlucoTrack Inc

2022 Q4 Form 10-Q Financial Statement

#000149315222031787 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $683.0K $495.0K $320.0K
YoY Change -11.41% 54.69% -21.95%
% of Gross Profit
Research & Development $604.0K $434.0K $447.0K
YoY Change -17.6% -2.91% -6.88%
% of Gross Profit
Depreciation & Amortization $4.000K $5.000K $11.00K
YoY Change -55.56% -54.55% -45.0%
% of Gross Profit
Operating Expenses $1.287M $929.0K $767.0K
YoY Change -14.43% 21.12% -13.82%
Operating Profit -$929.0K -$767.0K
YoY Change 21.12%
Interest Expense $13.00K $2.000K $9.000K
YoY Change 160.0% -77.78% -77.5%
% of Operating Profit
Other Income/Expense, Net -$13.00K -$1.000K -$46.00K
YoY Change 85.71% -97.83% -113.53%
Pretax Income -$1.287M -$928.0K -$804.0K
YoY Change -14.54% 15.42% 57.65%
Income Tax
% Of Pretax Income
Net Earnings -$1.287M -$928.0K -$804.0K
YoY Change -14.54% 15.42% 57.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.05
Diluted Earnings Per Share -$0.08 -$0.06 -$52.03K
COMMON SHARES
Basic Shares Outstanding 15.48M shares 15.47M shares 15.45M shares
Diluted Shares Outstanding 15.47M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.312M $3.241M $7.000M
YoY Change -61.86% -53.7% -34.64%
Cash & Equivalents $2.312M $3.241M $7.000M
Short-Term Investments
Other Short-Term Assets $67.00K $187.0K $65.00K
YoY Change 55.81% 187.69% 8.33%
Inventory $288.0K
Prepaid Expenses
Receivables $66.00K
Other Receivables $0.00
Total Short-Term Assets $2.379M $3.428M $7.419M
YoY Change -61.03% -53.79% -33.22%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $44.00K $136.0K
YoY Change -42.03% -67.65% -54.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $19.00K $39.00K $78.00K
YoY Change -62.75% -50.0% 30.0%
Total Long-Term Assets $59.00K $83.00K $214.0K
YoY Change -63.13% -61.21% -40.56%
TOTAL ASSETS
Total Short-Term Assets $2.379M $3.428M $7.419M
Total Long-Term Assets $59.00K $83.00K $214.0K
Total Assets $2.438M $3.511M $7.633M
YoY Change -61.09% -54.0% -33.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $672.0K $713.0K $645.0K
YoY Change 6.5% 10.54% -23.21%
Accrued Expenses $325.0K $0.00 $32.00K
YoY Change 1313.04% -100.0% -77.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.013M $965.0K $898.0K
YoY Change 14.72% 7.46% -31.97%
LONG-TERM LIABILITIES
Long-Term Debt $195.0K $191.0K $201.0K
YoY Change -7.14% -4.98% 5.79%
Other Long-Term Liabilities $0.00 $0.00 $33.00K
YoY Change -100.0% -100.0% 65.0%
Total Long-Term Liabilities $195.0K $191.0K $234.0K
YoY Change -14.1% -18.38% 11.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.013M $965.0K $898.0K
Total Long-Term Liabilities $195.0K $191.0K $234.0K
Total Liabilities $1.208M $1.156M $1.132M
YoY Change 8.83% 2.12% -26.01%
SHAREHOLDERS EQUITY
Retained Earnings -$101.9M -$100.6M
YoY Change 4.55%
Common Stock $103.1M $102.9M
YoY Change 0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.230M $2.355M $6.501M
YoY Change
Total Liabilities & Shareholders Equity $2.438M $3.511M $7.633M
YoY Change -61.09% -54.0% -33.45%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$1.287M -$928.0K -$804.0K
YoY Change -14.54% 15.42% 57.65%
Depreciation, Depletion And Amortization $4.000K $5.000K $11.00K
YoY Change -55.56% -54.55% -45.0%
Cash From Operating Activities -$940.0K -$608.0K -$894.0K
YoY Change -3.39% -31.99% 16.1%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K $0.00 $0.00
YoY Change -25.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.000K $0.00 $0.00
YoY Change
Cash From Investing Activities $5.000K $0.00 $0.00
YoY Change -225.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -940.0K -608.0K -894.0K
Cash From Investing Activities 5.000K 0.000 0.000
Cash From Financing Activities 0.000
Net Change In Cash -935.0K -608.0K -894.0K
YoY Change -4.3% -31.99% 10.37%
FREE CASH FLOW
Cash From Operating Activities -$940.0K -$608.0K -$894.0K
Capital Expenditures -$3.000K $0.00 $0.00
Free Cash Flow -$937.0K -$608.0K -$894.0K
YoY Change -3.3% -31.99% 10.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
15000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001506983
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2021Q4 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41141
dei Entity Registrant Name
EntityRegistrantName
GLUCOTRACK, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0668934
dei Entity Address Address Line1
EntityAddressAddressLine1
8 Ariel Sharon Street
dei Entity Address Address Line2
EntityAddressAddressLine2
P.O. Box 6037607
dei Entity Address City Or Town
EntityAddressCityOrTown
Or Yehuda
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7760049
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
(8) 675-7878
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GCTK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15476665 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3241000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6062000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
187000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
43000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
3428000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
6105000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
40000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
39000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
51000 usd
CY2022Q3 us-gaap Assets
Assets
3511000 usd
CY2021Q4 us-gaap Assets
Assets
6265000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
713000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
631000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
252000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
229000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
965000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
883000 usd
CY2022Q3 us-gaap Due To Officers Or Stockholders Noncurrent
DueToOfficersOrStockholdersNoncurrent
191000 usd
CY2021Q4 us-gaap Due To Officers Or Stockholders Noncurrent
DueToOfficersOrStockholdersNoncurrent
210000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17000 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
191000 usd
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
227000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1156000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1110000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15476665 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15476665 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15452285 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15452285 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102906000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
102612000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
30000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000 usd
CY2022Q3 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
18000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100614000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97466000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
GCTK Stock To Be Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockToBeIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
18000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5155000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3511000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6265000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1363000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1077000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
434000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
447000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
136000 usd
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
113000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1782000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1323000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
495000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
207000 usd
us-gaap Operating Expenses
OperatingExpenses
3145000 usd
us-gaap Operating Expenses
OperatingExpenses
2536000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
929000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
767000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3145000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2536000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-929000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-767000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-46000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-2000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
21000 usd
CY2022Q3 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
2000 usd
CY2021Q3 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
9000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-928000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-804000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3112000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2572000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-929000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-808000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15468279 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15448923 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6501000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
36000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
20000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15473521 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15451726 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8982000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
25000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
66000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6501000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
7286000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-804000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
274000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-928000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000 usd
CY2022Q3 GCTK Stock To Be Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockToBeIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
18000 usd
CY2022Q3 GCTK Stock To Be Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockToBeIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
18000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
76000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2355000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3148000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2561000 usd
us-gaap Depreciation
Depreciation
19000 usd
us-gaap Depreciation
Depreciation
33000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-41000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
274000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
66000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
38000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
38000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
8000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
5000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
148000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
9000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
117000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-223000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
51000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-142000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2789000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2796000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-40000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-14000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2833000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2807000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6113000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9885000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3280000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7078000 usd
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 13
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100614000 usd
CY2022Q3 us-gaap Cash
Cash
3241000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6562279 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6356344 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zPF84MbFwmTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z7yzLouBXvrh">Use of estimates in the preparation of financial statements</span></b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated interim condensed financial statements, the most significant estimates and assumptions relate to the going concern assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3241000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6062000 usd

Files In Submission

Name View Source Status
0001493152-22-031787-index-headers.html Edgar Link pending
0001493152-22-031787-index.html Edgar Link pending
0001493152-22-031787.txt Edgar Link pending
0001493152-22-031787-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gctk-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gctk-20220930_cal.xml Edgar Link unprocessable
gctk-20220930_pre.xml Edgar Link unprocessable
gctk-20220930_def.xml Edgar Link unprocessable
gctk-20220930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed